Three Questions With CEO Andrew Knudten

The gene and cell therapy industry is experiencing rapid growth, driven by technological advancements, an increasing number of development programs, and recent product approvals. One exciting development is the FDA's active support for this progress, particularly in addressing challenges for rare diseases. However, the industry must work closely with regulators to ensure that manufacturing and testing processes meet the standards needed for successful therapeutic development. This includes resolving common challenges like product purity and bridging early manufacturing processes to commercial viability. With the right technology, expertise, and collaborative efforts, these obstacles are solvable.

Learn more about what is exciting Advanced Medicine Partners CEO Andrew Knudten about the gene and cell therapy industry by accessing the full Q&A below.